JPMorgan Downgrades Pacira Pharmaceuticals (PCRX) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Truist Securities Double Downgrades Pacira Pharmaceuticals (PCRX) to Sell
August 13, 2024 6:06 AM EDTTruist Securities analyst Les Sulewski downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Sell with a price target of $8.00 (from $30.00).
The analyst comments "We revisit our core thesis on PCRX after our follow-up call with KOL conveys generic Exparel launch is... More



